secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001628280-24-042893
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint
--------------------------------------------------------------------------------

- Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
- GAAP diluted EPS $0.94; adjusted diluted EPS $1.21; FY 2024 adj. EPS guidance raised to $4.64-$4.70.
- FreeStyle Libre CGM sales >$1.6B (+20.7% organic); new $7B share repurchase authorized; quarterly dividend $0.55.
- Partnered with Medtronic to connect CGM with insulin devices; launched OTC Lingo CGM in U.S.; completed VOLT-AF trial enrollment.
- Nutrition organic +3.4% (Adult +9.1%); Diagnostics organic ex-COVID +3.3% (Core Lab +4.5%); Established Pharma organic +7.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828024042893/0001628280-24-042893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828024042893/abt-20241016.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer